Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan
Biological and Pharmaceutical Bulletin · 2023
DOI: 10.1248/bpb.b22-00868 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Yoshitsugu Hino und 6 weiteren Autor:innen. Beteiligte Einrichtung: Global Regulatory Science, Gifu Pharmaceutical University. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Regulatory Science, Gifu Pharmaceutical University.
- Copenhagen Center for Regulatory Science, University of Copenhagen.
- Utrecht Centre for Pharmaceutical Policy and Regulation, Utrecht University.
- Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida.
Zitieren
APA
Hino, Y., Okada, M., Hallgreen, C. E., De Bruin, M. L., Doty, R. E., Matsumaru, N., & Tsukamoto, K. (2023). Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b22-00868
Vancouver
Hino Y, Okada M, Hallgreen CE, De Bruin ML, Doty RE, Matsumaru N, et al. Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b22-00868
BibTeX
@article{Hino2023,
author = {Hino, Yoshitsugu and Okada, Miu and Hallgreen, Christine Erikstrup and De Bruin, Marie Louise and Doty, Randell E and Matsumaru, Naoki and Tsukamoto, Katsura},
title = {Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan},
journal = {Biological and Pharmaceutical Bulletin},
year = {2023},
doi = {10.1248/bpb.b22-00868}
}
EUVIMED